Thought Leadership
Time, Place, and Staying Power in VC
OpenLoop Raises $8M Series A
Superconductive Series B
Our Vision for 2022 and Beyond
Prolucent Health Expands Management Team
Tava Health Raises $10M Series A
Prolucent Health Series A Funding
PathologyWatch Raises $25M for Skincare AI Research
These U.S. States Have The Most Startup Investment For Their Size

How The Patient-Centric Interdependence Model Is Revolutionizing Healthcare
June 29, 2021
How The Patient-Centric Interdependence Model Is Revolutionizing Healthcare
By Dan Lambert, Technology Partner at SpringTide This article originally appeared in Forbes on May 13, 2021 If you are like 64% of American households, you own…

Algorithms Do Not A Company Make
May 22, 2020
Algorithms Do Not A Company Make
By Dan Lambert, Technology Partner at SpringTide The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR…

Necessity is the Mother of Invention
April 1, 2020
Necessity is the Mother of Invention
By Austin Walters, Managing Partner of SpringTide
Living in a markedly different cultural environment, I began to learn that societies develop comparative strengths and weaknesses over time in response to conditions on the ground.

SpringTide’s “n of 1” Philosophy
April 1, 2020
SpringTide’s “n of 1” Philosophy
The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”

PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists
March 25, 2020
PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists
SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year.